Leukemia stem cell: “We need runway.”
Tumor metabolism: “Already shipped an internal ketone factory.”
Ferroptosis: “Am I a joke to you?”
Cancer biology has many rude surprises, but this one has a crisp Silicon Valley flavor: some leukemia stem cells appear to be manufacturing their own ketone bodies, not as a diet plan, not as wellness content, but as survival infrastructure.
A new Cell Stem Cell commentary by Zhao, Zhuang, and Gan spotlights work from Han and colleagues showing that leukemic stem cells in acute myeloid leukemia, or AML, can run a private ketogenesis program to protect themselves from ferroptosis, a form of iron-driven cell death that makes vulnerable cells essentially rust from the inside out (doi:10.1016/j.stem.2026.04.022; doi:10.1016/j.stem.2026.04.013).
That is not just “cells use energy.” That is “cells found a security exploit and built a subscription business around it.”
The Startup Nobody Asked For
Ketone bodies are usually framed as emergency fuel. When glucose runs low, the liver makes molecules like beta-hydroxybutyrate, or BHB, which can help power tissues such as the brain. Very responsible. Very infrastructure-core.
But Han et al. found something sneakier: leukemic stem cells, the stubborn little founders of AML relapse, seem to make BHB inside themselves. These are not ordinary leukemia bulk cells. Leukemic stem cells are the seed population that can keep disease going, resist treatment, and re-launch the whole malignant app after therapy tries to uninstall it.
In the study, AML leukemic stem cells showed elevated fatty acid oxidation and high expression of HMGCS2, a key enzyme in ketogenesis. When researchers deleted Hmgcs2, BHB levels fell, leukemic stem cell function weakened, and leukemia progression slowed in mouse and human AML models. Normal blood-forming stem cells were much less affected, which is exactly the kind of therapeutic window researchers dream about before reality shows up with a clipboard.
Ferroptosis: The Rust-Based Kill Switch
Ferroptosis is not apoptosis, the tidy cell-suicide program biology textbooks love. Ferroptosis is messier and more metal. It depends on iron and lipid peroxidation, meaning fatty components of cell membranes get chemically damaged until the cell can no longer keep its act together.
For cancer therapy, that is tempting. Many cancer cells live close to oxidative stress already, like a startup running production on one laptop and vibes. Push them a bit further, and they may collapse.
Recent reviews have framed ferroptosis as a promising vulnerability in cancer and leukemia, especially because cancer stem cells often depend on altered iron handling, lipid metabolism, and antioxidant defenses (doi:10.1038/s41568-022-00459-0; doi:10.1007/s12015-025-11016-1). The trick is finding the exact protective systems malignant cells use, then pulling out the support beam without flattening healthy tissue.
This paper points to one such support beam: BHB.
BHB: Not Just Fuel, Apparently Also Legal Counsel
The big mechanistic twist is that BHB did not merely feed the leukemia cells. It helped them dodge ferroptosis by changing lipid remodeling through epigenetic regulation of FADS2, an enzyme involved in fatty acid desaturation. In plain English: BHB helped alter the cell membrane’s ingredients so the leukemia stem cells were less vulnerable to the oxidative chain reaction that ferroptosis needs.
That is annoyingly elegant. The leukemia stem cell is not just buying more batteries. It is redesigning the hardware case so the battery fire never starts.
This fits a broader theme in AML research: leukemic stem cells are metabolically weird in ways that matter. They can depend on mitochondrial activity, fatty acid metabolism, amino acid pathways, and other energy-routing choices that make them different from their healthier neighbors. A Blood review recently summarized how metabolism helps stem-cell-driven leukemia survive, adapt, and resist therapy (doi:10.1182/blood.2022018258).
Translation: leukemia stem cells have product-market fit in the bone marrow, and metabolism is part of their growth stack.
Please Do Not Turn This Into Diet Advice
A giant neon caveat belongs here: this does not mean a ketogenic diet causes AML, treats AML, prevents AML, or should be changed by anyone with cancer based on this paper. The study is about cell-intrinsic ketogenesis inside leukemic stem cells. That is different from what you ate for breakfast.
Biology enjoys making words overlap just enough to cause chaos at dinner parties.
The real therapeutic idea is much more precise: if leukemic stem cells rely on HMGCS2-driven internal ketone production to suppress ferroptosis, then blocking that pathway could make them easier to kill. Pair that with ferroptosis-inducing strategies, existing AML therapies, or future targeted drugs, and you might have a way to hit the relapse-driving cells that often survive standard treatment.
That “if” is doing work. These findings need replication, deeper safety testing, drug-development reality checks, and eventually clinical trials. Mouse models are useful, but they are not tiny patients with calendars, comorbidities, and insurance portals.
Why This One Sticks
AML treatment has improved, but relapse remains a brutal problem because the cells that survive therapy can be the ones most capable of rebuilding disease. So a pathway that seems enriched in leukemic stem cells, tied to ferroptosis resistance, and less essential for normal blood stem cells is worth attention.
Not because it is ready for the clinic tomorrow. It is not.
Because it gives researchers a cleaner target map. The enemy is no longer just “cancer cells are resilient.” It is “these leukemia stem cells may be protecting themselves with an HMGCS2-BHB-FADS2 axis that blocks ferroptotic death.”
That is actionable biology. Also, frankly, rude biology.
References
-
Zhao X, Zhuang L, Gan B. Ketone bodies as guardians of leukemic stemness through ferroptosis suppression. Cell Stem Cell. 2026;33(6):901-903. doi:10.1016/j.stem.2026.04.022
-
Han X, Wang K, Ma W, et al. A ketogenesis-ferroptosis axis maintains leukemic stem cell survival and leukemia progression. Cell Stem Cell. 2026;33(6):1016-1030.e6. doi:10.1016/j.stem.2026.04.013
-
Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nature Reviews Cancer. 2022;22:381-396. doi:10.1038/s41568-022-00459-0
-
Rattigan KM, Zarou MM, Helgason GV. Metabolism in stem cell-driven leukemia: Parallels between hematopoiesis and immunity. Blood. 2023;141:2553-2565. doi:10.1182/blood.2022018258
-
Wang Z, Yang Q, Yang Y, et al. Regulating Ferroptosis in Leukemic Stem Cells: From Stemness Preservation to Targeted Differentiation Strategies. Stem Cell Reviews and Reports. 2026;22:296-323. doi:10.1007/s12015-025-11016-1
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.